| Joshua A Foster, CRNA | |
|
409 Julee Cir, Brandon, MS 39042-6003 | |
| (601) 906-8765 | |
| Not Available |
| Full Name | Joshua A Foster |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 13 Years |
| Location | 409 Julee Cir, Brandon, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619256690 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | R865752 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Our Lady Of The Lake Regional Medical Center | Baton rouge, LA | Hospital |
| Franklin Medical Center | Winnsboro, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesiology Group Associates Inc | 0042110298 | 151 |
| Riverside Anesthesia Llc | 3476527946 | 3 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.
Accelarad's team first recognized the need for the virtualization of radiology more than 10 years ago. Over the past six years, the industry has readily adopted cloud-based medical image exchanges, as evidenced by the thousands of physicians who share nearly half a billion images via Accelarad each year.
ULURU Inc. announced today that advanced applications of the Nanoflex technology, related to future products in drug delivery and tissue engineering, will be presented at the 11th annual New Cardiovascular Horizons Meeting to be held in New Orleans, Louisiana on June 2-5, 2010. This meeting is the largest medical meeting that focuses on peripheral artery disease and peripheral interventions, including wound care for vascular ulcers, the application of advanced therapies for limb salvage and amputation prevention.
Millions of poor Nigerians will gain access to the most effective combination treatment for malaria at a fraction of its current cost, following the successful conclusion of negotiations between the United Kingdom Department for International Development (DFID) funded Partnership for Transforming Health Systems (PATHS2) and a variety of international and national stakeholders in Nigeria this week.
› Verified 9 days ago
| Entity Name | Mid-louisiana Anesthesia Consultants, Apmc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205888914 PECOS PAC ID: 3971408733 Enrollment ID: O20031204000583 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.
Accelarad's team first recognized the need for the virtualization of radiology more than 10 years ago. Over the past six years, the industry has readily adopted cloud-based medical image exchanges, as evidenced by the thousands of physicians who share nearly half a billion images via Accelarad each year.
ULURU Inc. announced today that advanced applications of the Nanoflex technology, related to future products in drug delivery and tissue engineering, will be presented at the 11th annual New Cardiovascular Horizons Meeting to be held in New Orleans, Louisiana on June 2-5, 2010. This meeting is the largest medical meeting that focuses on peripheral artery disease and peripheral interventions, including wound care for vascular ulcers, the application of advanced therapies for limb salvage and amputation prevention.
Millions of poor Nigerians will gain access to the most effective combination treatment for malaria at a fraction of its current cost, following the successful conclusion of negotiations between the United Kingdom Department for International Development (DFID) funded Partnership for Transforming Health Systems (PATHS2) and a variety of international and national stakeholders in Nigeria this week.
› Verified 9 days ago
| Entity Name | Anesthesiology Group Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255399598 PECOS PAC ID: 0042110298 Enrollment ID: O20040113000117 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.
Accelarad's team first recognized the need for the virtualization of radiology more than 10 years ago. Over the past six years, the industry has readily adopted cloud-based medical image exchanges, as evidenced by the thousands of physicians who share nearly half a billion images via Accelarad each year.
ULURU Inc. announced today that advanced applications of the Nanoflex technology, related to future products in drug delivery and tissue engineering, will be presented at the 11th annual New Cardiovascular Horizons Meeting to be held in New Orleans, Louisiana on June 2-5, 2010. This meeting is the largest medical meeting that focuses on peripheral artery disease and peripheral interventions, including wound care for vascular ulcers, the application of advanced therapies for limb salvage and amputation prevention.
Millions of poor Nigerians will gain access to the most effective combination treatment for malaria at a fraction of its current cost, following the successful conclusion of negotiations between the United Kingdom Department for International Development (DFID) funded Partnership for Transforming Health Systems (PATHS2) and a variety of international and national stakeholders in Nigeria this week.
› Verified 9 days ago
| Entity Name | Riverside Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518918556 PECOS PAC ID: 3476527946 Enrollment ID: O20040820000805 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.
Accelarad's team first recognized the need for the virtualization of radiology more than 10 years ago. Over the past six years, the industry has readily adopted cloud-based medical image exchanges, as evidenced by the thousands of physicians who share nearly half a billion images via Accelarad each year.
ULURU Inc. announced today that advanced applications of the Nanoflex technology, related to future products in drug delivery and tissue engineering, will be presented at the 11th annual New Cardiovascular Horizons Meeting to be held in New Orleans, Louisiana on June 2-5, 2010. This meeting is the largest medical meeting that focuses on peripheral artery disease and peripheral interventions, including wound care for vascular ulcers, the application of advanced therapies for limb salvage and amputation prevention.
Millions of poor Nigerians will gain access to the most effective combination treatment for malaria at a fraction of its current cost, following the successful conclusion of negotiations between the United Kingdom Department for International Development (DFID) funded Partnership for Transforming Health Systems (PATHS2) and a variety of international and national stakeholders in Nigeria this week.
› Verified 9 days ago
| Entity Name | Richland Parish Hospital Service District No 1-b |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255370144 PECOS PAC ID: 2163481599 Enrollment ID: O20041011000012 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.
Accelarad's team first recognized the need for the virtualization of radiology more than 10 years ago. Over the past six years, the industry has readily adopted cloud-based medical image exchanges, as evidenced by the thousands of physicians who share nearly half a billion images via Accelarad each year.
ULURU Inc. announced today that advanced applications of the Nanoflex technology, related to future products in drug delivery and tissue engineering, will be presented at the 11th annual New Cardiovascular Horizons Meeting to be held in New Orleans, Louisiana on June 2-5, 2010. This meeting is the largest medical meeting that focuses on peripheral artery disease and peripheral interventions, including wound care for vascular ulcers, the application of advanced therapies for limb salvage and amputation prevention.
Millions of poor Nigerians will gain access to the most effective combination treatment for malaria at a fraction of its current cost, following the successful conclusion of negotiations between the United Kingdom Department for International Development (DFID) funded Partnership for Transforming Health Systems (PATHS2) and a variety of international and national stakeholders in Nigeria this week.
› Verified 9 days ago
| Entity Name | Smso Anesthesia, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730134636 PECOS PAC ID: 7012970627 Enrollment ID: O20041104001054 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.
Accelarad's team first recognized the need for the virtualization of radiology more than 10 years ago. Over the past six years, the industry has readily adopted cloud-based medical image exchanges, as evidenced by the thousands of physicians who share nearly half a billion images via Accelarad each year.
ULURU Inc. announced today that advanced applications of the Nanoflex technology, related to future products in drug delivery and tissue engineering, will be presented at the 11th annual New Cardiovascular Horizons Meeting to be held in New Orleans, Louisiana on June 2-5, 2010. This meeting is the largest medical meeting that focuses on peripheral artery disease and peripheral interventions, including wound care for vascular ulcers, the application of advanced therapies for limb salvage and amputation prevention.
Millions of poor Nigerians will gain access to the most effective combination treatment for malaria at a fraction of its current cost, following the successful conclusion of negotiations between the United Kingdom Department for International Development (DFID) funded Partnership for Transforming Health Systems (PATHS2) and a variety of international and national stakeholders in Nigeria this week.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joshua A Foster, CRNA 409 Julee Cir, Brandon, MS 39042-6003 Ph: (601) 906-8765 | Joshua A Foster, CRNA 409 Julee Cir, Brandon, MS 39042-6003 Ph: (601) 906-8765 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.
Accelarad's team first recognized the need for the virtualization of radiology more than 10 years ago. Over the past six years, the industry has readily adopted cloud-based medical image exchanges, as evidenced by the thousands of physicians who share nearly half a billion images via Accelarad each year.
ULURU Inc. announced today that advanced applications of the Nanoflex technology, related to future products in drug delivery and tissue engineering, will be presented at the 11th annual New Cardiovascular Horizons Meeting to be held in New Orleans, Louisiana on June 2-5, 2010. This meeting is the largest medical meeting that focuses on peripheral artery disease and peripheral interventions, including wound care for vascular ulcers, the application of advanced therapies for limb salvage and amputation prevention.
Millions of poor Nigerians will gain access to the most effective combination treatment for malaria at a fraction of its current cost, following the successful conclusion of negotiations between the United Kingdom Department for International Development (DFID) funded Partnership for Transforming Health Systems (PATHS2) and a variety of international and national stakeholders in Nigeria this week.
› Verified 9 days ago
Mrs. Amanda Kim Covault, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2510 Lakeland Drive, Brandon, MS 39232 Phone: 601-355-1234 Fax: 601-326-3566 | |
Ms. Carla A Lambright, Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 106 Rosewood Ln, Brandon, MS 39042 Phone: 601-825-7121 | |
Mrs. Amanda Myrick Cribbs, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 133 Ridge Cv, Brandon, MS 39042 Phone: 601-825-4429 | |
Mrs. Carly B Mcdaniel, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 221 Boxwood Cir, Brandon, MS 39047 Phone: 601-942-1594 |